Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma Has Eye On Pharmacopeia’s DARA For Blood Pressure

This article was originally published in The Pink Sheet Daily

Executive Summary

DARA, a first-in-class dual-acting angiotensin and endothelin receptor antagonist in development for hypertension and diabetic nephropathy, is in Phase II development.

You may also be interested in...



Wooing Partners, Pharmacopeia Shifts DARA To Kidney Disease

Cash-light firm’s move away from the crowded hypertension space could clinch a deal.

Wooing Partners, Pharmacopeia Shifts DARA To Kidney Disease

Cash-light firm’s move away from the crowded hypertension space could clinch a deal.

Pharmacopeia Targets 2009 For SARM Phase II After Gaining Program From Bristol

Company licenses the Phase I selective androgen receptor modulator for muscle wasting from Bristol in exchange for research support.

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel